期刊文献+

补肾中药对糖皮质激素性骨质疏松模型大鼠的干预作用 被引量:3

Treating effects of nourishing-kidney herbs on rat models with glucocorticoid-induced osteoporosis
原文传递
导出
摘要 目的采用地塞米松肌注法建立糖皮质激素性骨质疏松(glucocorticoid-inducedosteoporosis,GIO)大鼠模型,观察补肾中药的防治作用。方法Wistar大鼠60只,雌雄各半,按体重分层随机法分为正常组、模型组、补肾组。均采用肌注地塞米松的方法造模,2.5mg/kg·次^-1,2次/周,连续9周。测定离体股骨骨密度(BMD)及血清骨代谢指标。结果模型组模型大鼠BMD明显降低(0.109±0.007)g/cm^2,血清骨吸收标记物TRAP含量明显升高(9.96±1.15)μg/ml;补肾组模型大鼠BMD(0.116±0.007)g/cm^2,血清TRAP含量降低(5.76±O.85)μg/ml。结论补肾中药对糖皮质激素诱导的GIO大鼠模型有一定拮抗作用。 Objective To observe the effects of nourishing-kidney herbs on rat model with glucocorticoid-induced osteoporosis. Methods 60 Wistar rats male and female half and half were randomly divided into a normal group, a model group and a nourishing-kidney group. By intramuscular injection of dexamethasone (2.5 mg/kg) twice a week to replicate osteoporosis rat model. All groups were treated for 9 weeks. Detected the BMD of femur in vitro and determined the bone metabolism marker in serum by biochemical process. Results The BMD decreased obviously (0.109± 0.007)g/cm^2 and the content of TRAP in serum increased evidently (9.96± 1.15) μg/ml in the model group. In the nourishing-kidney group, the BMD was up-regulated (0.116 ± 0.007)g/cm^2, and TRAP down-regulated(5.76 ±0.85)μg/mh Conclusion Intramuscular injection of dexamethasone can induce GIO rat model, and nourishing-kidney herbs have the effect of anti-osteoporosis.
出处 《国际中医中药杂志》 2012年第2期134-136,共3页 International Journal of Traditional Chinese Medicine
基金 国家教育部博士点科研基金资助项目(项目编号:No.200801620003) 国家“973”计划课题资助项目(项目编号:No.2010CB530401)
关键词 糖皮质激素性骨质疏松症 大鼠模型:补肾中药 Glucocorticoid-induced osteoporosis, Dexamethasone: Animal model Nourishing-kidney
  • 相关文献

参考文献4

二级参考文献23

共引文献42

同被引文献39

  • 1孟彦彬,孙盛,高巍.牛膝中对成骨样细胞UMR106有促进增殖作用的活性成分研究[J].时珍国医国药,2007,18(12):2947-2948. 被引量:7
  • 2Migliaccio S, Brama M, Malavoha N. Management of glucocorticoids- induced osteoporosis : role of teriparatide [ J ]. Ther Clin Risk Manag, 2009,5(2) :305-310.
  • 3Pereira RM, Carvalho JF, Paula AP, et al. Guidelines for the preven- tion and treatment of glucocorticoid-induced osteoporosis [ J ]. Rev Bras Reumatol, 2012,52 ( 4 ) : 569 -593.
  • 4Ventura A, Brunetti G, Colucci S, et al. Glucocorticoid-Induced osteo- porosis in children with 21-hydroxylase deficiency [ J ]. Biomed Res Int,2013,5 ( 1 ) :250462.
  • 5Yao W, Cheng Z, Busse C ,et al. Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and pro- longed suppression of osteogenesis: a longitudinal study of gene ex- pression in bone tissue from glucocorticoid-treated mice [ J ]. Arthritis Rheum,2008,58 ( 6 ) : 1674-1686.
  • 6Macsai CE, Foster BK, Xian CJ. Roles of Writ signalling in bone growth, remodelling, skeletal disorders and fracture repair [J]. J Cell Physio1,2008,215 ( 3 ) :578-587.
  • 7Yan Y, Tang D, Chen M, et al. Axin2 controls bone remodeling through the 13-catenin-BMP signaling pathway in adult mice [ J ]. J Cell Sci ,2009,122 ( 19 ) :3566-3578.
  • 8v Olkku A, Mahonen A. Calreticulin mediated glucocorticoid receptor export is involved in beta-catenin translocation and Wnt signaling in- hibition in human osteoblastic ceils [ J ]. Bone, 2009,44 ( 4 ) : 555- 565.
  • 9Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis [ Jl. Endocrinol Metab Clin North Am,2012,41 (3) :595-611.
  • 10Almeida M, O' Brien CA. Basic biology of skeletal aging:role of stress response pathways[ Jl. J Gerontol A Biol Sci Med Sci ,2013,68(10) : 1197-1208. DOI: 10. 1093/gerona/glt079.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部